Therapeutic blockade of HER2 signaling in HER2+ breast cancer can lead to the upregulation/reactivation of ER-regulated gene transcription or increased ER dependency as shown in Fig. 1b. This evidence concerns the gene ERBB2 and breast carcinoma.